PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Recognizing and managing on toxicities in cancer immunotherapy.

Abstract Over the past 4 years, cancer immunotherapy has significantly prolonged survival time of patients with prostate cancer, melanoma, lung cancer, and liver cancer, but its side effects are also impressive. Different types of the immune therapeutic agents have different on-target or off-target toxicity due to high affinity or weak specificity, respectively. Treatment toxicity spectrums vary greatly even in patients with the same type of cancer. Common toxicities are fevers, chills, diarrhea colitis, maculopapular rash, hepatitis, and hormone gland disorder; therefore, routine monitoring of thyroid function, liver function, renal function, and complete blood count are absolutely necessary once treatment begins. Some side effects are reversible, and can be processed through the standard medicines. However, serious toxicities are lethal, which should be frequently followed-up, identified at an early stage and immediately symptomatic treated by high-dose immunosuppressors. In this case, thereafter, the same agent should not be challenged again.
PMID
Related Publications

Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.

Autoimmunity associated with immunotherapy of cancer.

Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Endocrine side effects induced by immune checkpoint inhibitors.

Authors

Mayor MeshTerms
Keywords

Toxicities

cancer

immunotherapy

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28351299
OWN - NLM
STAT- MEDLINE
DA  - 20170329
DCOM- 20170407
LR  - 20170407
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 3
DP  - 2017 Mar
TI  - Recognizing and managing on toxicities in cancer immunotherapy.
PG  - 1010428317694542
LID - 10.1177/1010428317694542 [doi]
AB  - Over the past 4 years, cancer immunotherapy has significantly prolonged survival 
      time of patients with prostate cancer, melanoma, lung cancer, and liver cancer,
      but its side effects are also impressive. Different types of the immune
      therapeutic agents have different on-target or off-target toxicity due to high
      affinity or weak specificity, respectively. Treatment toxicity spectrums vary
      greatly even in patients with the same type of cancer. Common toxicities are
      fevers, chills, diarrhea colitis, maculopapular rash, hepatitis, and hormone
      gland disorder; therefore, routine monitoring of thyroid function, liver
      function, renal function, and complete blood count are absolutely necessary once 
      treatment begins. Some side effects are reversible, and can be processed through 
      the standard medicines. However, serious toxicities are lethal, which should be
      frequently followed-up, identified at an early stage and immediately symptomatic 
      treated by high-dose immunosuppressors. In this case, thereafter, the same agent 
      should not be challenged again.
FAU - Yang, Liu
AU  - Yang L
AD  - Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan, China.
FAU - Yu, Huifang
AU  - Yu H
AD  - Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan, China.
FAU - Dong, Shuang
AU  - Dong S
AD  - Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan, China.
FAU - Zhong, Yi
AU  - Zhong Y
AD  - Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan, China.
FAU - Hu, Sheng
AU  - Hu S
AD  - Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/classification/*pathology
MH  - Humans
MH  - Immunotherapy/*adverse effects
MH  - Neoplasms/*immunology/pathology/*therapy
OTO - NOTNLM
OT  - *Toxicities
OT  - *cancer
OT  - *immunotherapy
EDAT- 2017/03/30 06:00
MHDA- 2017/04/08 06:00
CRDT- 2017/03/30 06:00
AID - 10.1177/1010428317694542 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Mar;39(3):1010428317694542. doi: 10.1177/1010428317694542.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>